Evidence map›Paper›PMID 41450989›Full record

ArticlePakistan journal of medical sciences2025

Development and validation of a nomogram for predicting pulmonary embolism in patients with non-small cell lung cancer.

Xiaoting Wu, Shanshan Tang

Abstract read
In one paragraph

Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaoting WuXiaoting Wu, Department of Respiratory and Critical Care, First People's Hospital of Linping District, Hangzhou, Zhejiang Province 311199, P.R. China.
Shanshan TangShanshan Tang, Department of Respiratory and Critical Care, First People's Hospital of Linping District, Hangzhou, Zhejiang Province 311199, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: In patients with non-small cell lung cancer (NSCLC) complicated by pulmonary embolism (PE), the clinical manifestations become more complex and the diagnosis is more difficult. We aimed to develop and validate an individualized nomogram for differentiating the PE of NSCLC. Methodology: Patients with NSCLC at the First People's Hospital of Linping District, Hangzhou were enrolled from September 2021 to March 2024. Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate logistic regression analyses were performed to recognize risk factors. An individualized nomogram was subsequently developed. The model's performance was validated using the receiver operating characteristic (ROC) curve, calibration plot, and decision curve analysis (DCA). Results: We enrolled 390 NSCLC patients, of whom 89 (22.8%) had PE. Using multivariate logistic regression, we finally identified seven independent risk factors for PE: pathological type, tumor-node-metastasis (TNM) staging, indwelling central venous catheter (CVC), chemotherapy, hemoglobin, white blood cell count (WBC), and neutrophil-to-lymphocyte ratio (NLR). The model showed good predictive ability, with an area under the ROC curve of 0.909 (95% CI: 0.875-0.942). The calibration curves of the model showed good agreement between actual and predicted probabilities. The ROC and DCA curves demonstrated that the nomogram exhibited a good predictive performance. Conclusions: The nomogram model for predicting the risk of PE in NSCLC has good predictive performance and is potentially useful for screening of high-risk patients in clinical practice.

Indexed as

Nomogram modelNon-small cell lung cancerPulmonary embolismRisk prediction

Identifiers

PMID41450989
PMCPMC12728689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.